ラバクフォサジン
**ラバクフォサジン**は、主に犬のリンパ腫（B細胞およびT細胞）や多発性骨髄腫の治療に使用される新規の抗悪性腫瘍薬です。 > **臨床上の警告：** 本剤は強力な細胞毒性薬です。化学療法の安全ガイドラインに従い、訓練を受けた専門スタッフのみが調製および投与を行う必要があります。
作用機序: Rabacfosadine is a **prodrug** of the nucleotide analogue **PMEG** (9-(2-phosphonylmethoxyethyl)guanine). Once converted, it acts by **inhibiting DNA polymerases** → preventing DNA synthesis → causing **cytotoxicity** and apoptosis in rapidly dividing cells, such as neoplastic lymphocytes.
動物種別の用量
- Lymphoma (B and T cell) and multiple myeloma · 0.82-1 mg/kg · IV · once every 21 days · over 30 min · Has been used in combination with doxorubicin at weeks 0, 6, 12 as part of an alternating protocol.
用量は獣医療従事者向けの臨床リファレンスです。必ず最新の添付文書と個々の患者で確認してください。
投与経路
禁忌
- Known hypersensitivity
- Pre-existing bone marrow suppression
- Liver dysfunction
- Known pulmonary disease
- Susceptibility to pulmonary fibrosis
有害事象
- Myelosuppression
- Gastrointestinal adverse events (including haemorrhagic gastroenteritis)
- Liver enzyme activity elevation
- Azotaemia
- Fever
- Weight loss
- Lethargy
- Dermatological signs
- Pulmonary fibrosis
- Injected sclera
- Urinary signs (proteinuria, glycosuria)
モニタリング
- Complete Blood Count (CBC) for myelosuppression
- Liver enzyme activity
- Renal parameters (BUN, Creatinine) and Urinalysis (for proteinuria/glycosuria)
- Respiratory rate and effort (monitor for pulmonary fibrosis)
- Clinical signs of gastrointestinal toxicity
過量投与
Information not provided in the monograph. Due to its cytotoxic nature, overdose is likely to cause severe myelosuppression, gastrointestinal toxicity, and potentially fatal pulmonary fibrosis. Aggressive supportive care and monitoring are indicated.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。